Precision oncology: A new era of cancer clinical trials.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Cancer Letters

• Publication date

  2017-02-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.canlet.2016.03.015PMID 26987624PMCID PMC5023449
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neutrophil-to-lymphocyte ratio as a potential prognostic factor of disease-free survival in high-risk renal cell carcinoma: Analysis of the S-TRAC trial.

  2018cited by this paper
• Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma.

  2016cited by this paper
• Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.

  2015cited by this paper
• The Brave New World of clinical cancer research: Adaptive biomarker‐driven trials integrating clinical practice with clinical research

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

  2015cited by this paper
• ALCHEMIST: Bringing genomic discovery and targeted therapies to early‐stage lung cancer

  2015cited by this paper
• Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials.

  2015cited by this paper
• Pembrolizumab versus Ipilimumab in Advanced Melanoma.

  2015cited by this paper
• An overview of the design and conduct of the BATTLE trials.

  2015cited by this paper
• Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial

  2014cited by this paper
• Adaptive Clinical Trials

  2014cited by this paper
• Ceritinib in ALK-rearranged non-small-cell lung cancer.

  2014cited by this paper
• Ceritinib in ALK-rearranged non-small-cell lung cancer.

  2014cited by this paper
• Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

  2013cited by this paper
• Companion Diagnostics in Oncology - Current Status and Future Aspects

  2013cited by this paper
• Alliance A091102: Phase II study of MLN8237 (alisertib) in advanced/metastatic sarcoma.

  2013cited by this paper
• Evaluating many treatments and biomarkers in oncology: a new design.

  2013influential reference
• Reports from the 2010 Clinical and Translational Cancer Research Think Tank Meeting: Design Strategies for Personalized Therapy Trials

  2012cited by this paper
• Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

  2011cited by this paper
• The BATTLE trial: personalizing therapy for lung cancer.

  2011cited by this paper
• Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

  2011cited by this paper
• Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

  2010cited by this paper
• Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

  2010cited by this paper
• Randomized clinical trials with biomarkers: design issues.

  2010cited by this paper
• F1000 highlights

  2010cited by this paper
• Predictive biomarker validation in practice: lessons from real trials

  2010cited by this paper
• Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.

  2009cited by this paper
• I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy

  2009cited by this paper
• Bayesian adaptive design for targeted therapy development in lung cancer — a step toward personalized medicine

  2008cited by this paper
• Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials.

  2008cited by this paper
• Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

  2008cited by this paper
• Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

  2008cited by this paper
• Cetuximab for the treatment of colorectal cancer.

  2007cited by this paper
• Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset

  2007cited by this paper
• Article on Evaluating the Efficiency of Targeted Designs

  2006cited by this paper
• On the efficiency of targeted clinical trials

  2005cited by this paper
• Clinical trial designs for predictive marker validation in cancer treatment trials.

  2005cited by this paper
• Clinical Trial Designs for Prospective Validation of Biomarkers

  2005cited by this paper
• Evaluating the Efficiency of Targeted Designs for Randomized Clinical Trials

  2004cited by this paper
• Cetuximab in the treatment of colorectal cancer.

  2004cited by this paper
• Issues in clinical trial design for tumor marker studies.

  2002cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper

• Rapid Assessment of Target-Binding Fractions in Theranostic and Imaging Agents Using Size-Exclusion HPLC

  2026cites this paper
• Methodological Insights on Biomarker‐Based Patient Selection: A Review of Scientific Advice Procedures at the European Medicines Agency

  2025cites this paper
• Lactylation in digestive system tumors: from mechanisms to therapeutic target

  2025cites this paper
• Acceptance and Utilization of Real-World Evidence among Cancer Care Physicians in the USA: A National Survey

  2025cites this paper
• Understanding drug resistance in breast cancer: Mechanisms and emerging therapeutic strategies

  2025cites this paper
• Bayesian adaptive enrichment design in multi-arm clinical trials: The BayesAET package for R users

  2025cites this paper
• SIG: Graph-Based Cancer Subtype Stratification With Gene Mutation Structural Information

  2024cites this paper
• Unjustified Partiality or Impartial Bias? Reckoning with Age and Disability Discrimination in Cancer Clinical Trials

  2024cites this paper
• New Insights into Colorectal Cancer through the Lens of Precision Oncology and Personalized Medicine: Multi-Omics Helps Aging of Predisposed People.

  2024cites this paper
• Target-Driven Tissue-Agnostic Drug Approvals—A New Path of Drug Development

  2024cites this paper
• Identification of modules and key genes associated with breast cancer subtypes through network analysis

  2024cites this paper
• Evolution of Phase II Oncology Trial Design: from Single Arm to Master Protocol

  2023cites this paper
• New generation biomarkers for the detection of prostate cancer

  2022cites this paper
• Study designs for clinical trials applied to personalised medicine: a scoping review

  2022cites this paper
• Operational complexity versus design efficiency: challenges of implementing a phase IIa multiple parallel cohort targeted treatment platform trial in advanced breast cancer

  2022cites this paper
• Defining a Core Data Set for the Economic Evaluation of Precision Oncology.

  2022cites this paper
• Pharmacophore Modeling, 3D QSAR, Molecular Dynamics Studies and Virtual Screening on Pyrazolopyrimidines as anti-Breast Cancer Agents

  2022cites this paper
• Effective Cancer Subtype and Stage Prediction via Dropfeature-DNNs

  2021cites this paper
• Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer

  2021cites this paper
• Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO–Friends of Cancer Research Prior Therapies Work Group

  2021cites this paper
• Methoden klinischer Prüfung in der Onkologie

  2021cites this paper
• Bayesian adaptive trial design for a continuous biomarker with possibly nonlinear or nonmonotone prognostic or predictive effects

  2021cites this paper
• How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment

  2021cites this paper
• Comparison of Joint and Landmark Modeling for Predicting Cancer Progression in Men With Castration-Resistant Prostate Cancer

  2021cites this paper
• Genomic Strategies for Personalized Cancer Therapy

  2020cites this paper
• Limited bias effect of intratumoral heterogeneity on genetic profiling of hepatocellular carcinoma.

  2020cites this paper
• Quantitative Evidence Synthesis Methods for the Assessment of the Effectiveness of Treatment Sequences for Clinical and Economic Decision Making: A Review and Taxonomy of Simplifying Assumptions

  2020cites this paper
• A Qualitative Study on the Differences Between Trial Populations and the Approved Therapeutic Indications of Antineoplastic Agents by 3 Regulatory Agencies From 2010 to 2018.

  2020cites this paper
• “Pharmacogenetics of Cancer” - Cancer Drug Resistance special issue

  2020cites this paper
• An integrated prognosis model of pharmacogenomic gene signature and clinical information for diffuse large B-cell lymphoma patients following CHOP-like chemotherapy

  2020cites this paper
• Applications of personalised signalling network models in precision oncology.

  2020cites this paper
• Precision medicine in rare tumors and the need for multicenter trials and international collaboratives: Sinonasal cancer as paradigm.

  2020cites this paper
• Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference

  2020cites this paper
• Prognosis for intrahepatic cholangiocarcinoma patients treated with postoperative adjuvant transcatheter hepatic artery chemoembolization.

  2020cites this paper
• The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review.

  2020cites this paper
• Identification of UBE2T as an independent prognostic biomarker for gallbladder cancer

  2020cites this paper
• Current status of Bayesian clinical trials for oncology, 2020

  2020cites this paper
• New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.

  2019cites this paper
• Bias and stereotyping among research and clinical professionals: Perspectives on minority recruitment for oncology clinical trials

  2019cites this paper
• Disease modification in neurodegenerative diseases

  2019cites this paper
• Designing precision medicine trials to yield a greater population impact

  2019cites this paper
• Engineered T Cell Therapy for Cancer in the Clinic

  2019cites this paper
• Challenges and shifting paradigms in clinical trials in oncology: the case for immunological and targeted therapies

  2019cites this paper
• Adaptive, Iterative, Long-Term Personalized Therapy Management in a Case of Stage IV Refractory NSCLC

  2019cites this paper
• Definitions and statistical properties of master protocols for personalized medicine in oncology

  2018cites this paper
• Feature Addressing the rarity and complexities of sarcomas

  2018cites this paper
• The Many Different Designs of Phase II Trials in Oncology

  2018cites this paper
• Personalized medicine: biomarkers and companion diagnostics

  2018cites this paper
• Intensive care medicine in 2050: clinical trials designs

  2018cites this paper
• Tumor-Agnostic Drug Development.

  2018cites this paper
• A pooled analysis of published, basket trials in cancer medicine.

  2018cites this paper
• Describing the Reportable Range Is Important for Reliable Treatment Decisions: A Multiple Laboratory Study for Molecular Tumor Profiling Using Next-Generation Sequencing.

  2018cites this paper
• Clinical and molecular aspects of breast cancer: Targets and therapies.

  2018cites this paper
• Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers

  2018cites this paper
• Innovations in Clinical Trial Design in the Era of Molecular Profiling.

  2017cites this paper
• Radiomics strategies for risk assessment of tumour failure in head-and-neck cancer

  2017cites this paper
• Exome Sequencing Identifies Potentially Druggable Mutations in Nasopharyngeal Carcinoma

  2017cites this paper
• Precision medicine in pediatric oncology

  2017cites this paper
• Report on the FDA-AACR Immuno-oncology Drug Development Workshop

  2017cites this paper
• Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples.

  2016cites this paper
• The Utility of Adaptive Designs in Publicly Funded Confirmatory Trials

  2016cites this paper
• Development and validation of an ultra-high sensitive next-generation sequencing assay for molecular diagnosis of clinical oncology.

  2016cites this paper
• Application of Multimodality Imaging Fusion Technology in Diagnosis and Treatment of Malignant Tumors under the Precision Medicine Plan

  2016cites this paper